Simply Wall St.
How The Revvity (RVTY) Narrative Is Shifting With Higher Targets And Tempered Growth Assumptions
📈
AI Sentiment
Highly Positive
8/10
- Home
- RVTY
RVTY
Revvity Inc.
as of 03-09-2026 3:19pm EST
$91.32
$0.43
-0.47%
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
| Founded: | 1937 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 11.8B | IPO Year: | 1994 |
| Target Price: | $113.00 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 15 |
| Dividend Yield: | Dividend Payout Frequency: | quarterly | |
| EPS: | 2.07 | EPS Growth: | -5.91 |
| 52 Week Low/High: | $81.36 - $119.02 | Next Earning Date: | 04-27-2026 |
| Revenue: | $3,311,822,000 | Revenue Growth: | -13.48% |
| Revenue Growth (this year): | 6.34% | Revenue Growth (next year): | 5.10% |
| P/E Ratio: | 44.32 | Index: | |
| Free Cash Flow: | 509.4M | FCF Growth: | -5.95% |
Stock Insider Trading Activity of Revvity Inc. (RVTY)
Victor Miriame
Sell
Please See Remarks
RVTY Feb 24, 2026
Avg Cost/Share
$97.13
Shares
1,862
Total Value
$180,856.06
Owned After
18,122
SEC Form 4
McMurry-Heath Michelle
Sell
Director
RVTY Feb 23, 2026
Avg Cost/Share
$97.26
Shares
600
Total Value
$58,356.00
Owned After
4,233
SEC Form 4
Goldberg Joel S
Sell
Please See Remarks
RVTY Feb 5, 2026
Avg Cost/Share
$100.96
Shares
12,717
Total Value
$1,274,356.53
Owned After
49,540
Singh Prahlad R.
Sell
Please See Remarks
RVTY Feb 5, 2026
Avg Cost/Share
$100.63
Shares
25,525
Total Value
$2,557,858.90
Owned After
132,245
Vohra Tajinder S
Sell
Please See Remarks
RVTY Feb 2, 2026
Avg Cost/Share
$104.50
Shares
5,756
Total Value
$601,502.00
Owned After
10,442
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Victor Miriame | RVTY | Please See Remarks | Feb 24, 2026 | Sell | $97.13 | 1,862 | $180,856.06 | 18,122 | |
| McMurry-Heath Michelle | RVTY | Director | Feb 23, 2026 | Sell | $97.26 | 600 | $58,356.00 | 4,233 | |
| Goldberg Joel S | RVTY | Please See Remarks | Feb 5, 2026 | Sell | $100.96 | 12,717 | $1,274,356.53 | 49,540 | |
| Singh Prahlad R. | RVTY | Please See Remarks | Feb 5, 2026 | Sell | $100.63 | 25,525 | $2,557,858.90 | 132,245 | |
| Vohra Tajinder S | RVTY | Please See Remarks | Feb 2, 2026 | Sell | $104.50 | 5,756 | $601,502.00 | 10,442 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 2, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 2, 2026 · 100% conf.
AI Prediction SELL
1D
-0.76%
$106.28
5D
-4.42%
$102.36
20D
-2.62%
$104.29
Price: $107.09 Prob +5D: 0% AUC: 1.000
0000031791-26-000007
pki-202602020000031791FALSE00000317912026-02-022026-02-020000031791us-gaap:CommonStockMember2026-02-022026-02-020000031791pki:One875NotesDue2026MemberMember2026-02-022026-02-02
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2026
Revvity, Inc. (Exact Name of Registrant as Specified in its Charter)
Massachusetts001-0507504-2052042 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (IRS Employer Identification No.)
77 4th Avenue,Waltham,Massachusetts02451 (Address of Principal Executive Offices)(Zip Code)
Registrant’s telephone number, including area code: (781) 663-6900 Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s) Name of each exchange on which registered
Common stock, $1 par value per shareRVTYThe New York Stock Exchange 1.875% Notes due 2026RVTY 26The New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On February 2, 2026, Revvity, Inc. announced its financial results for the fourth quarter and fiscal year ended December 28, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01. Financial Statements and Exhibits
(d) Exhibits
EXHIBIT INDEX
Exhibit No.Description
99.1* Press Release entitled “Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025”, issued by Revvity, Inc. on February 2, 2026
104 Cover Page Interactive Data File (embedded within the Inline XBRL)
* This exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
REVVITY, INC.
Date: February 2, 2026 By: /s/ Maxwell Krakowiak Maxwell Krakowiak Senior Vice President and Chief Financial Officer
2025 Q4 Q4 2025 Earnings
8-K SELL Jan 13, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLJan 13, 2026 · 100% conf.
AI Prediction SELL
1D
-0.76%
$106.28
5D
-4.42%
$102.36
20D
-2.62%
$104.29
Price: $107.09 Prob +5D: 0% AUC: 1.000
0000031791-26-000003
pki-202601120000031791FALSE00000317912026-01-122026-01-120000031791us-gaap:CommonStockMember2026-01-122026-01-120000031791pki:One875NotesDue2026MemberMember2026-01-122026-01-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026
Revvity, Inc. (Exact Name of Registrant as Specified in its Charter)
Massachusetts001-0507504-2052042 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (IRS Employer Identification No.)
77 4th Avenue,Waltham,Massachusetts02451 (Address of Principal Executive Offices)(Zip Code)
Registrant’s telephone number, including area code: (781) 663-6900 Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s) Name of each exchange on which registered
Common stock, $1 par value per shareRVTYThe New York Stock Exchange 1.875% Notes due 2026RVTY 26The New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On January 12, 2026, Revvity, Inc. (the “Company”) announced preliminary expectations with respect to certain financial results for the fourth quarter ended December 28, 2025 and announced that the Company will release its fourth quarter and full year 2025 financial results on February 2, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 7.01. Regulation FD Disclosure On January 13, 2026, Dr. Prahlad Singh, President and Chief Executive Officer of the Company, is scheduled to make a presentation to the 44th Annual J. P. Morgan Healthcare Conference. A copy of the presentation materials is furnished as Exhibit 99.2 to this Current Report on Form 8-K.
The information in this Form 8-K (including Exhibit 99.1 and Exhibit 99.2) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
EXHIBIT INDEX
Exhibit No.Description
99.1* Press Release entitled “Revvity to Hold Earnings Call on Monday, February 2, 2026; Provides Update on Financial Performance”, issued by Revvity, Inc. on January 12, 2026
99.2* Revvity, Inc. Presentation to the 44th Annual J.P. Morgan Healthcare Conference, January 13, 2026.
104 Cover Page Interactive Data File (embedded within the Inline XBRL)
* This exhibit relating to Item 2.02 and 7.01 shall be deemed to be furnished, and not filed..
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
REVVITY, INC.
Date: January 13, 2025By: /s/ Maxwell Krakowiak Maxwell Krakowiak Senior Vice President and Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Oct 27, 2025
2025
Q3
Q3 2025 Earnings
8-KOct 27, 2025
0000031791-25-000032
pki-202510270000031791FALSE00000317912025-10-272025-10-270000031791us-gaap:CommonStockMember2025-10-272025-10-270000031791pki:One875NotesDue2026MemberMember2025-10-272025-10-27
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2025
Revvity, Inc. (Exact Name of Registrant as Specified in its Charter)
Massachusetts001-0507504-2052042 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (IRS Employer Identification No.)
77 4th Avenue,Waltham,Massachusetts02451 (Address of Principal Executive Offices)(Zip Code)
Registrant’s telephone number, including area code: (781) 663-6900 Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s) Name of each exchange on which registered
Common stock, $1 par value per shareRVTYThe New York Stock Exchange 1.875% Notes due 2026RVTY 26The New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On October 27, 2025, Revvity, Inc. announced its financial results for the third quarter ended September 28, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01. Financial Statements and Exhibits
(d) Exhibits
EXHIBIT INDEX
Exhibit No.Description
99.1* Press Release entitled “Revvity Announces Financial Results for the Third Quarter of 2025”, issued by Revvity, Inc. on October 27, 2025.
104 Cover Page Interactive Data File (embedded within the Inline XBRL)
* This exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
REVVITY, INC.
Date: October 27, 2025 By: /s/ Maxwell Krakowiak Maxwell Krakowiak Senior Vice President and Chief Financial Officer
Latest Revvity Inc. News
RVTY Breaking Stock News: Dive into RVTY Ticker-Specific Updates for Smart Investing
StockStory
Tenet Healthcare, Revvity, Avantor, Azenta, and Elanco Shares Plummet, What You Need To Know
📉
AI Sentiment
Negative
2/10
Zacks
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
📊
AI Sentiment
Positive
7/10
StockStory
2 Cash-Producing Stocks for Long-Term Investors and 1 We Find Risky
➖
AI Sentiment
Neutral
4/10
Compare RVTY vs Leading Stocks
See how RVTY stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RVTY Revvity Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.